L3VLUP
ProSign in

PHVS · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

PHVSJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • PHVS
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterPHVSJNJ
Q3 2020none listed holders, n.a.30 holders, $26.2bn
Q4 2020none listed holders, n.a.32 holders, $26.6bn
Q1 20214 holders, $74m31 holders, $25.3bn
Q2 20212 holders, $45m37 holders, $25.6bn
Q3 20211 holders, $41m40 holders, $24.1bn
Q4 20211 holders, $39m33 holders, $25.2bn
Q1 20221 holders, $46m35 holders, $28.2bn
Q2 20221 holders, $55m33 holders, $26.9bn
Q3 20221 holders, $20m36 holders, $25.4bn
Q4 20221 holders, $36m35 holders, $27.6bn
Q1 20231 holders, $25m42 holders, $24.5bn
Q2 20231 holders, $51m38 holders, $25.0bn
Q3 20231 holders, $67m37 holders, $18.9bn
Q4 20232 holders, $105m31 holders, $19.0bn
Q1 20241 holders, $84m32 holders, $19.7bn
Q2 20241 holders, $69m35 holders, $20.4bn
Q3 20241 holders, $68m28 holders, $22.3bn
Q4 20241 holders, $70m37 holders, $20.4bn
Q1 20251 holders, $57m32 holders, $20.5bn
Q2 20251 holders, $64m31 holders, $18.4bn
Q3 20251 holders, $91m32 holders, $23.7bn
Q4 20251 holders, $101m29 holders, $27.8bn
Q1 20261 holders, $103m34 holders, $35.6bn
Q2 20263 holders, $185m33 holders, $39.1bn
PHVS

Pharvaris N V

Holders
1
Reported value
$101m
Buyers
14
Sellers
3

Breadth +11 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
29
Reported value
$27.8bn
Buyers
13
Sellers
26

Breadth -13 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2025

Among the 30 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Both (0)

No tracked manager lists every one of them.

Only PHVS (1)

Viking Global Investors LP

Only JNJ (29)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, D. E. Shaw & Co., Dodge & Cox, Element Capital Management LLC, Fidelity (FMR LLC), Freestone Grove Partners LP, GAMCO Investors Inc, Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Markel Group Inc, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Rokos Capital Management LLP, Squarepoint Ops LLC, and 4 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →